Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma

Melanoma Res. 2022 Apr 1;32(2):131-132. doi: 10.1097/CMR.0000000000000801.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents, Immunological* / adverse effects
  • Female
  • Humans
  • Ipilimumab / therapeutic use
  • Melanoma* / pathology
  • Neoplasms, Second Primary*
  • Nivolumab / therapeutic use
  • Pregnancy
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • Antineoplastic Agents, Immunological
  • Ipilimumab
  • Nivolumab